About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00377637

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF ...

Lead sponsor: Hoffmann-La Roche•28 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Hoffmann-La Roche

Collaborators

Aspreva Pharmaceuticals

Age

12 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•male or female patients, 12-75 years of age;
•diagnosis of systemic lupus erythematosus;
•kidney biopsy within 6 months of study, with histological diagnosis of lupus nephritis;
•laboratory evidence of active nephritis.

Exclusion Criteria

•continuous dialysis starting \>2 weeks before randomization into induction phase, and/or with an anticipated duration of \>8 weeks;
•previous or planned kidney transplant;
•other clinically significant active medical conditions.

Related studies

RECRUITINGPhase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277 · Lupus Nephritis

RECRUITINGPhase 2

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208 · Lupus Nephritis

RECRUITINGPhase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis

RECRUITINGPhase 1/2

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

NCT06947460 · Refractory Lupus Nephritis, Systemic Sclerosis, and more

RECRUITINGEARLY Phase 1

Safety and Efficacy of ONT01 in Lupus

NCT07107659 · Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 6, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment370

Start dateJul 2005

Last updatedDec 6, 2011

Condition

Lupus Nephritis

Locations shown

Huntsville, Alabama

La Jolla, California

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 6, 2011Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions